Literature DB >> 27008872

Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients.

T Fauchier1, L Hasseine2, M Gari-Toussaint2, V Casanova3, P M Marty2,4,5, C Pomares2,4,5.   

Abstract

Pneumocystis jirovecii pneumonia (PCP) is an acute and life-threatening lung disease caused by the fungus Pneumocystis jirovecii The presentation of PCP in HIV-positive patients is well-known and consists of a triad of dyspnea, fever, and cough, whereas the presentation of PCP in HIV-negative patients is atypical and consists of a sudden outbreak, O2 desaturation, and a rapid lethal outcome without therapy. Despite the availability of direct and indirect identification methods, the diagnosis of PCP remains difficult. The cycle threshold (CT) values obtained by quantitative PCR (qPCR) allow estimation of the fungal burden. The more elevated that the fungal burden is, the higher the probability that the diagnosis is pneumonia. The purposes of the present study were to evaluate the CT values to differentiate colonization and pneumonia in a population of immunocompromised patients overall and patients stratified on the basis of their HIV infection status. Testing of bronchoalveolar lavage (BAL) fluid samples from the whole population of qPCR-positive patients showed a mean CT value for patients with PCP of 28 (95% confidence interval [CI], 26 to 30) and a mean CT value for colonized patients of 35 (95% CI, 34 to 36) (P < 10(-3)). For the subgroup of HIV-positive patients, we demonstrated that a CT value below 27 excluded colonization and a CT value above 30 excluded PCP with a specificity of 100% and a sensitivity of 80%, respectively. In the subgroup of HIV-negative patients, we demonstrated that a CT value below 31 excluded colonization and a CT value above 35 excluded PCP with a specificity of 80% and a sensitivity of 80%, respectively. Thus, qPCR of BAL fluid samples is an important tool for the differentiation of colonization and pneumonia in P. jirovecii-infected immunocompromised patients and patients stratified on the basis of HIV infection status with different CT values.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27008872      PMCID: PMC4879311          DOI: 10.1128/JCM.03174-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  71 in total

Review 1.  Pneumocystis pneumonia.

Authors:  Charles F Thomas; Andrew H Limper
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

2.  Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study.

Authors:  Chifumbe Chintu; Victor Mudenda; Sebastian Lucas; Andrew Nunn; Kennedy Lishimpi; Daniel Maswahu; Francis Kasolo; Peter Mwaba; Ganapati Bhat; Hiroshi Terunuma; Alimuddin Zumla
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

3.  A real-time polymerase chain reaction assay for detection of Pneumocystis from bronchoalveolar lavage fluid.

Authors:  Rodney C Arcenas; James R Uhl; Seanne P Buckwalter; Andrew H Limper; Dana Crino; Glenn D Roberts; Nancy L Wengenack
Journal:  Diagn Microbiol Infect Dis       Date:  2006-01-19       Impact factor: 2.803

Review 4.  Pneumocystis jirovecii pneumonia in kidney transplantation.

Authors:  N Goto; S Oka
Journal:  Transpl Infect Dis       Date:  2011-10-31       Impact factor: 2.228

5.  Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study.

Authors:  N A Maskell; D J Waine; A Lindley; J C T Pepperell; A E Wakefield; R F Miller; R J O Davies
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

6.  Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection.

Authors:  Tatsuji Enomoto; Arata Azuma; Ayumi Kohno; Kazuyo Kaneko; Hitoshi Saito; Minako Kametaka; Jiro Usuki; Akihiko Gemma; Shoji Kudoh; Seiichi Nakamura
Journal:  Respirology       Date:  2009-11-23       Impact factor: 6.424

7.  Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.

Authors:  Mark Thomas; Priscilla Rupali; Andrew Woodhouse; Rod Ellis-Pegler
Journal:  Scand J Infect Dis       Date:  2009

8.  Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study.

Authors:  Florence Robert-Gangneux; Sorya Belaz; Matthieu Revest; Pierre Tattevin; Stéphane Jouneau; Olivier Decaux; Sylviane Chevrier; Yves Le Tulzo; Jean-Pierre Gangneux
Journal:  J Clin Microbiol       Date:  2014-07-09       Impact factor: 5.948

9.  Accuracy of a routine real-time PCR assay for the diagnosis of Pneumocystis jirovecii pneumonia.

Authors:  Judith Fillaux; Sonia Malvy; Muriel Alvarez; Richard Fabre; Sophie Cassaing; Bruno Marchou; Marie-Denise Linas; Antoine Berry
Journal:  J Microbiol Methods       Date:  2008-06-21       Impact factor: 2.363

10.  Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis.

Authors:  F P Ognibene; J H Shelhamer; G S Hoffman; G S Kerr; D Reda; A S Fauci; R Y Leavitt
Journal:  Am J Respir Crit Care Med       Date:  1995-03       Impact factor: 21.405

View more
  40 in total

1.  Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China.

Authors:  Yan-Hui Chen; Xue-Yao Fang; Yue-Ting Li; Yan-Ling Liu; Ya-Ping Hang; Yan-Ping Xiao; Xing-Wei Cao; Qiao-Shi Zhong; Long-Hua Hu
Journal:  Braz J Microbiol       Date:  2020-05-03       Impact factor: 2.476

2.  Molecular Diagnosis of Pneumocystis jirovecii Pneumonia by Use of Oral Wash Samples in Immunocompromised Patients: Usefulness and Importance of the DNA Target.

Authors:  Lidia Goterris; Miguel Angel Mancebo Fernández; Juan Aguilar-Company; Vicenç Falcó; Isabel Ruiz-Camps; M Teresa Martín-Gómez
Journal:  J Clin Microbiol       Date:  2019-11-22       Impact factor: 5.948

Review 3.  Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches.

Authors:  Marjorie Bateman; Rita Oladele; Jay K Kolls
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

4.  Possible Diagnostic Delays and Missed Prevention Opportunities in Pneumocystis Pneumonia Patients Without HIV: Analysis of Commercial Insurance Claims Data-United States, 2011-2015.

Authors:  Jeremy A W Gold; Brendan R Jackson; Kaitlin Benedict
Journal:  Open Forum Infect Dis       Date:  2020-06-29       Impact factor: 3.835

Review 5.  [Pneumocystis jirovecii pneumonia in patients with autoimmune diseases].

Authors:  S Blaas
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

Review 6.  A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.

Authors:  Liang Ma; Ousmane H Cissé; Joseph A Kovacs
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

7.  Recognition of Diagnostic Gaps for Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics Laboratories Consortium (FDLC).

Authors:  Sean X Zhang; N Esther Babady; Kimberly E Hanson; Amanda T Harrington; Paige M K Larkin; Sixto M Leal; Paul M Luethy; Isabella W Martin; Preeti Pancholi; Gary W Procop; Stefan Riedel; Seyedmojtaba Seyedmousavi; Kaede V Sullivan; Thomas J Walsh; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

8.  The prevalence of laboratory-confirmed Pneumocystis jirovecii in HIV-infected adults in Africa: A systematic review and meta-analysis.

Authors:  Nicola K Wills; David S Lawrence; Elizabeth Botsile; Mark W Tenforde; Joseph N Jarvis
Journal:  Med Mycol       Date:  2021-07-14       Impact factor: 4.076

9.  Comparison of quantitative real-time PCR and direct immunofluorescence for the detection of Pneumocystis jirovecii.

Authors:  Bhavani Moodley; Stefano Tempia; John Andrew Frean
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

10.  Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway.

Authors:  Stine Grønseth; Tormod Rogne; Raisa Hannula; Bjørn Olav Åsvold; Jan Egil Afset; Jan Kristian Damås
Journal:  BMC Infect Dis       Date:  2021-07-07       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.